Challenges in assessing the clinical utility and economic value of immune checkpoint inhibitor therapies of Cancer

Advances in the immunotherapy of cancer have prolonged survival for cancer patients, but the clinical and financial impact of treatments must be considered in determining the overall clinical utility and economic value of therapeutic agents. Quality-adjusted life years and incremental cost-effective...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Peter Paul, Eton, Omar, Garrison, Louis P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6724271/
https://www.ncbi.nlm.nih.gov/pubmed/31481112
http://dx.doi.org/10.1186/s40425-019-0707-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6724271/
https://www.ncbi.nlm.nih.gov/pubmed/31481112
http://dx.doi.org/10.1186/s40425-019-0707-9

Ejemplares similares